,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,68 TW Alexander Drive,PO Box 13628,Research Triangle Park,NC,27709,United States,919 636 4530,https://www.fennecpharma.com,Biotechnology,Healthcare,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",36,"{'maxAge': 1, 'name': 'Mr. Rostislav  Raykov', 'age': 46, 'title': 'CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 614161, 'exercisedValue': 0, 'unexercisedValue': 5722718}",9,5,7,5,6,1693526400,1672444800,86400,2,10.76,10.95,10.52,10.95,10.76,10.95,10.52,10.95,0.0,0.246196,1900,1900,164,290,290,10.52,10.86,0,0,285855552,8.84,14.41,43.72886,11.0626,11.8026,0.0,0.0,CAD,296283200,0.0,15879840,26566500,74830,81406,1690761600,1693440000,0.0028,0.17321,0.5066,562.63,0.0041,-0.367,1672444800,1703980800,1688083200,-26442000,-1.32,1:3,1409875200,45.324,TOR,EQUITY,FRX.TO,FRX.TO,FENNEC PHARMACEUTICALS INC,Fennec Pharmaceuticals Inc.,992352600,America/Toronto,EDT,-14400000,10.76,none,14958000,0.563,25386000,4.606,5.117,6537000,0.247,-0.85595,1449000,-12047375,-21335000,0.94967,0.0,-3.66682,USD,
1,68 TW Alexander Drive,PO Box 13628,Research Triangle Park,NC,27709,United States,919 636 4530,https://www.fennecpharma.com,Biotechnology,Healthcare,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",36,"{'maxAge': 1, 'name': 'Mr. Robert C. Andrade', 'age': 47, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 428919, 'exercisedValue': 0, 'unexercisedValue': 2023772}",9,5,7,5,6,1693526400,1672444800,86400,2,10.76,10.95,10.52,10.95,10.76,10.95,10.52,10.95,0.0,0.246196,1900,1900,164,290,290,10.52,10.86,0,0,285855552,8.84,14.41,43.72886,11.0626,11.8026,0.0,0.0,CAD,296283200,0.0,15879840,26566500,74830,81406,1690761600,1693440000,0.0028,0.17321,0.5066,562.63,0.0041,-0.367,1672444800,1703980800,1688083200,-26442000,-1.32,1:3,1409875200,45.324,TOR,EQUITY,FRX.TO,FRX.TO,FENNEC PHARMACEUTICALS INC,Fennec Pharmaceuticals Inc.,992352600,America/Toronto,EDT,-14400000,10.76,none,14958000,0.563,25386000,4.606,5.117,6537000,0.247,-0.85595,1449000,-12047375,-21335000,0.94967,0.0,-3.66682,USD,
2,68 TW Alexander Drive,PO Box 13628,Research Triangle Park,NC,27709,United States,919 636 4530,https://www.fennecpharma.com,Biotechnology,Healthcare,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",36,"{'maxAge': 1, 'name': 'Mr. Adrian J. Haigh', 'age': 63, 'title': 'Chief Operating Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 40000, 'exercisedValue': 0, 'unexercisedValue': 0}",9,5,7,5,6,1693526400,1672444800,86400,2,10.76,10.95,10.52,10.95,10.76,10.95,10.52,10.95,0.0,0.246196,1900,1900,164,290,290,10.52,10.86,0,0,285855552,8.84,14.41,43.72886,11.0626,11.8026,0.0,0.0,CAD,296283200,0.0,15879840,26566500,74830,81406,1690761600,1693440000,0.0028,0.17321,0.5066,562.63,0.0041,-0.367,1672444800,1703980800,1688083200,-26442000,-1.32,1:3,1409875200,45.324,TOR,EQUITY,FRX.TO,FRX.TO,FENNEC PHARMACEUTICALS INC,Fennec Pharmaceuticals Inc.,992352600,America/Toronto,EDT,-14400000,10.76,none,14958000,0.563,25386000,4.606,5.117,6537000,0.247,-0.85595,1449000,-12047375,-21335000,0.94967,0.0,-3.66682,USD,
3,68 TW Alexander Drive,PO Box 13628,Research Triangle Park,NC,27709,United States,919 636 4530,https://www.fennecpharma.com,Biotechnology,Healthcare,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",36,"{'maxAge': 1, 'name': 'Ms. Ananya  Bhattacharya', 'title': 'Head of Medical Affairs & Safety', 'exercisedValue': 0, 'unexercisedValue': 0}",9,5,7,5,6,1693526400,1672444800,86400,2,10.76,10.95,10.52,10.95,10.76,10.95,10.52,10.95,0.0,0.246196,1900,1900,164,290,290,10.52,10.86,0,0,285855552,8.84,14.41,43.72886,11.0626,11.8026,0.0,0.0,CAD,296283200,0.0,15879840,26566500,74830,81406,1690761600,1693440000,0.0028,0.17321,0.5066,562.63,0.0041,-0.367,1672444800,1703980800,1688083200,-26442000,-1.32,1:3,1409875200,45.324,TOR,EQUITY,FRX.TO,FRX.TO,FENNEC PHARMACEUTICALS INC,Fennec Pharmaceuticals Inc.,992352600,America/Toronto,EDT,-14400000,10.76,none,14958000,0.563,25386000,4.606,5.117,6537000,0.247,-0.85595,1449000,-12047375,-21335000,0.94967,0.0,-3.66682,USD,
4,68 TW Alexander Drive,PO Box 13628,Research Triangle Park,NC,27709,United States,919 636 4530,https://www.fennecpharma.com,Biotechnology,Healthcare,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",36,"{'maxAge': 1, 'name': 'Mr. Mark  Gowland', 'title': 'Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",9,5,7,5,6,1693526400,1672444800,86400,2,10.76,10.95,10.52,10.95,10.76,10.95,10.52,10.95,0.0,0.246196,1900,1900,164,290,290,10.52,10.86,0,0,285855552,8.84,14.41,43.72886,11.0626,11.8026,0.0,0.0,CAD,296283200,0.0,15879840,26566500,74830,81406,1690761600,1693440000,0.0028,0.17321,0.5066,562.63,0.0041,-0.367,1672444800,1703980800,1688083200,-26442000,-1.32,1:3,1409875200,45.324,TOR,EQUITY,FRX.TO,FRX.TO,FENNEC PHARMACEUTICALS INC,Fennec Pharmaceuticals Inc.,992352600,America/Toronto,EDT,-14400000,10.76,none,14958000,0.563,25386000,4.606,5.117,6537000,0.247,-0.85595,1449000,-12047375,-21335000,0.94967,0.0,-3.66682,USD,
5,68 TW Alexander Drive,PO Box 13628,Research Triangle Park,NC,27709,United States,919 636 4530,https://www.fennecpharma.com,Biotechnology,Healthcare,"Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.",36,"{'maxAge': 1, 'name': 'Mr. Lei  Fang', 'title': 'Pres of Pharstat Inc', 'exercisedValue': 0, 'unexercisedValue': 0}",9,5,7,5,6,1693526400,1672444800,86400,2,10.76,10.95,10.52,10.95,10.76,10.95,10.52,10.95,0.0,0.246196,1900,1900,164,290,290,10.52,10.86,0,0,285855552,8.84,14.41,43.72886,11.0626,11.8026,0.0,0.0,CAD,296283200,0.0,15879840,26566500,74830,81406,1690761600,1693440000,0.0028,0.17321,0.5066,562.63,0.0041,-0.367,1672444800,1703980800,1688083200,-26442000,-1.32,1:3,1409875200,45.324,TOR,EQUITY,FRX.TO,FRX.TO,FENNEC PHARMACEUTICALS INC,Fennec Pharmaceuticals Inc.,992352600,America/Toronto,EDT,-14400000,10.76,none,14958000,0.563,25386000,4.606,5.117,6537000,0.247,-0.85595,1449000,-12047375,-21335000,0.94967,0.0,-3.66682,USD,
